KEAP1 and triple-A syndrome: Our observations that CTS significantly activates the Keap1-Nrf2 pathway and attenuates AAA formation prompted us to explore whether Nrf2 activation underlies CTS-mediated protective effects on AAA by using the Nrf2 transcriptional inhibitor ML385 68.